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Comparison of Estrogen receptors, Progesterone receptors and HER-2/neu
Expression between Primary and Metastatic Breast Carcinoma
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Department of Histopathology, Shaukat Khanum Cancer Hospital & Research Centre, Lahore.3

Abstract

Objective: To determine whether receptor status and HER-2/neu status remains same in primary and metastatic
breast carcinoma to corresponding lymph nodes of individual patients.
Methods: Estrogen receptors, progesterone receptors and HER-2/neu immunohistochemical stains were
performed on primary and metastatic breast carcinoma to axillary lymph nodes in 100 patients. Data was
collected on a Performa and age, tumour size, type, grade and expression of ER, PR and HER-2/neu on primary
and metastatic tumours were recorded.
Results: Hormone receptor status was compared between primary and metastatic tumours. Estrogen
receptor positivity was observed in 28% primary tumours which were reduced to 25% in metastatic carcinoma.
Progesterone receptors were positive in 28% primary tumours as compared to 22% in metastatic tumours.
Her-2/neu protein over expression was noted in 44% primary and 45% metastatic breast tumours respectively.
In case to case comparison ER, PR and HER-2/neu showed 91%, 88% and 95% concordance in primary and
metastatic tumours respectively.
Conclusion: ER, PR and HER-2/neu biomarkers showed significant concordance between primary and
metastatic breast carcinoma (JPMA 59:736; 2009).

Introduction

Breast cancer is a major medical problem with
significant public health and societal ramifications and is a
leading cause of Cancer death in women. Breast carcinoma is
the most common malignant neoplasm, with more than a
million cases occurring worldwide annually.1
Several risk factors for the development of breast
cancer have been established, and been proposed that the
common denominator for most of these factors is prolonged
estrogen stimulation operating on a genetically susceptible
background.2 Numerous studies suggest a strong link between
the female hormone, estrogen, and the development of breast
cancer. There is two to three times increased risk of breast
carcinoma if a first degree relative has breast cancer.3 Early
menarche, nulliparity, late age at first birth and late menopause
are all correlated with increased risk.4 According to some old
studies, exogenous hormone intake increases overall risk to
2.5 fold.5 More recently, a large cohort study and a case
control study have provided strong evidence for a greater
increase in breast cancer risk in women using hormone
replacement therapy than in those using estrogen alone.6 In
December 2002, the hormone estrogen was declared a known
human carcinogen by the National Toxicology Program.
Presence of hormone receptors in tumour tissue correlates
well with response to hormone therapy and chemotherapy.7
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status is helpful in selecting the patients most likely to receive
benefit from endocrine therapy, and provide prognostic
information on recurrence and survival since their expression
is related to the degree of the tumour differentiation. The
highest response rates to endocrine therapy are observed in
tumours, which are positive for estrogen and progesterone
receptors.8 Those patients with receptor positive tumours who
do suffer a recurrence usually do not have aggressive liver or
central nervous system involvement and they more commonly
experience a relapse in bone and soft tissue.9

The HER-2/neu proto-oncogene is amplified and as a
result over expressed in 25% to 30% of human breast cancer
and is usually associated with tumour aggressiveness and poor
prognosis.10 In breast cancer, several studies identified the
value of analyzing HER-2/neu as an approach to predict the
response of individual tumours to chemotherapy as well as in
the use of recombinant humanized antibodies (transtuzumab)
to the HER-2/neu protein in the active management of patients
with metastatic breast disease.11
Studies show significant concordance of ER and PR
expression between primary and metastatic breast carcinoma
to axillary lymph nodes.12-15 However there is slight decrease
in expression of these biomarkers in the metastatic tumours.
This effect may be due to tumour heterogeneity, a well-known
fact in anticancer chemo sensitivity, and may be reflected in
hormonal receptor status of metastatic breast carcinoma.
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Neoplastic cells from high-grade tumours may also loose
estrogen and progesterone receptors during the process of
metastasis. HER-2/neu expression, however, remains almost
same in primary and metastatic breast carcinomas.16,17 The
presented study compares the expression of these biomarkers
between primary and metastatic breast carcinoma.

Patients and Methods

One hundred patients of breast carcinoma with lymph
node metastases were selected for study from June 2004 to
September 2006 at pathology department Shaukat Khanum
Memorial Cancer Hospital and Research Centre, Lahore,
Pakistan. Mastectomy specimens of patients having primary
tumours and involved lymph nodes were included in the study.
Poorly preserved specimens were excluded. ER, PR and
HER-2/neu immunohistochemical stains were performed on
primary and metastatic breast tumours. Patients' information
was collected on a Performa.
Mastectomy specimens were sliced and fixed in 10%
buffered neutral formalin. Size of the tumour was recorded
and representative sections were taken from primary tumours.
Lymph nodes were dissected out from axillary tissue and
submitted. Sections were processed, cut and stained with
haematoxylin and eosin. Appropriate sections from primary
and metastatic tumours were selected for ER, PR and HER2/neu immunohistochemical stains. Thin sections (4 µm) were
cut. Immunohistochemical stains were performed according
to manufacturer's specifications.
Reporting criteria: A "quick score" method18 was used
for the quantification of Estrogen and progesterone receptors.
The quick score categories were based on both the intensity
and the proportion of brown nuclear staining. Two categories
A and B were made. In category "A" the proportion of positive
cells was assessed and scores were assigned from 1-6
according to percentage of positive cells (1= 0-4%; 2=5-19%;
3=20-39%; 4=40-59%; 5=60-79%; 6=80-100%).

The whole section was scanned at low power in order
to assess the general level of intensity throughout. The average
intensity corresponding to the presence of negative, weak,
intermediate and strong staining, was given a score from 0-3
respectively, and termed as category B. Category "A" was
multiplied by category "B". A score of 0 to 18 was obtained.
The score equal or more than 3 was considered as positive.
HER-2/neu was considered positive if more than 10%
cells showed moderate or strong complete membranous
staining. Weak, incomplete membrane staining or cytoplasmic
staining was considered negative.

Data Collection: ER, PR and HER-2/neu
immunohistochemical stains were performed on primary and
metastatic breast tumours. Information was collected on a
Performa. Patient's name, age, histology numbers, size of
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primary tumour, type of primary tumour, grade of tumour,
number of involved lymph nodes, size of largest metastatic
deposit and expression of ER, PR and HER-2/neu on primary
and metastatic tumour were recorded. Later on a master data
sheet was developed and all the information was entered.

Statistical Analysis: The comparison of the distribution
of histopathological characteristics between primary breast
and metastatic breast tumours was made using Fisher's exact
test for all biomarkers; estrogen receptors, progesterone
receptors and HER-2/neu. The exact Wilcoxon rank-sum test
was performed for quantitative variables. All statistical tests
were two sided. All results were judged as statistically
significant at a p value of 0.05 or less. All statistical
computations were done using StatXact 4 for Windows (Cytel
Inc., Cambridge, USA) and R, version 2.1 (R Development
Core Team 2005).19

Results

Immunohistochemical stains were performed on
hundred cases. Ages of the patients ranged from 23 to 84
years with the median of 45 years. (Table-1) Mean age was
46.27 ± 12.18 years. Most of the patients (73%) had ages
between 30 and 59 years. Eight patients were below 29 years
of age and one patient above 80 years. The tumour sizes
ranged from 1.0 to 12.5 cm with mean of 4.68 ± 2.27 cm.
Majority of the patients (85%) had invasive ductal
carcinomas, 9% had mixed tumours, 3% had invasive lobular
carcinoma and 3% had mucinous carcinomas. Two to 25
lymph nodes were isolated from modified radical mastectomy
Table-1: Pathologic Characteristics.
Variables
Total no of patients
Age of patients
Range
Mean
Tumour Size
Range
Mean
Tumour Type
Invasive ductal carcinoma (NOS)
Mixed invasive ductal carcinoma
and lobular carcinoma
Invasive lobular carcinoma
Mucinous carcinoma
Lymph node status
No of lymph nodes isolated in
each case
Range
Mean
No of involved lymph nodes
Range
Mean
Size of metastatic deposit
Range
Mean

Patient values
100
23 to 84 years
46.27 ± 12.18 years
1.0 to 12.5 cm
4.68 ± 2.27 cm
85 (85%)
9 (9%)
3
3

(3%)
(3%)

2.0 to 25
13.08 ± 5.49
1.0 to 25
6.78 ± 5.04
0.5 to 2.3cm
1.3 ± 0.51 cm
J Pak Med Assoc

Table-2: Comparison of biomarkers between
primary & metastatic tumours.
Biomarkers

Total no. of Patients
Estrogen Receptors (ER)
Positive
Negative
Progesterone Receptors (PR)
Positive
Negative
HER-2/neu
Positive
Negative

Table-3: Case to case comparison of biomarkers between
primary & metastatic carcinoma.
Pa value

Primary
Breast Tumor

Metastatic
Tumor

No (%)

No (%)

100

100

28 (28%)
72 (72%)

25 (25%)
75 (75%)

0.7488

28 (28%)
72 (72%)

22 (22%)
78 (78%)

0.4144

44 (44%)
56 (56%)

45 (45%)
55 (55%)

1.0000

a Fisher's Exact Test applied

specimens with mean of 13 ± 5.49 lymph nodes. The lymph
nodes involved by metastatic carcinoma ranged from 1 to 25
with the mean of 6 ± 5.04 lymph nodes. The size of metastatic
deposits ranged from 0.5cm to 2.3cm with Mean of 1.3 ± 0.51
cm (Table-1).

Hormonal receptor status was compared between
primary and metastatic tumours. Estrogen receptor positivity
was observed in 28% primary breast carcinomas. ER
expression reduced to 25% in metastatic breast carcinoma
with P value of 0.7488. Progesterone receptors were positive
in 28% primary tumours with reduced expression to 22% in
metastatic carcinomas. P value remained 0.4144. Her-2/neu
protein over expression was noted in 44% primary breast
tumours which was almost same as in the metastatic tumours.
It was over expressed in 45% metastatic tumours. P value was
1.0000 (Table-2). These P values confirm that there was no
statistically significant difference of biomarker expression
between primary and metastatic tumours.
In case to case comparison estrogen receptors were
positive both in primary and metastatic tumours in 22% cases
and negative in 69% cases. Therefore 91% cases had same
expression of estrogen receptors in primary and metastatic
breast carcinoma. Progesterone receptors showed 19%
positivity both in primary and metastatic tumours while 69%
cases were negative in both with 88% agreement between
primary and metastatic tumours. HER-2/neu was positive both
in primary and metastatic tumours in 42% cases and negative
in 53% cases with 95% concordance (Table-3).
When these stains were assessed under microscope,
the hormone receptors staining ranged from very strong with
quick score of 15, to weak nuclear staining patterns with quick
score of 3. Few tumours show variable expression of
hormonal receptors with strong, weak and negative staining
within the same tumour. When comparison between primary
and metastatic tumours was done, intensity and proportion of
Vol. 59, No. 11, November 2009

Biomarkers

Estrogen
Progesterone HER-2/neu
Receptors (ER) Receptors (PR)

Positive in both primary
and metastatic carcinoma
Negative in both primary
and metastatic carcinoma
Expression remained
unchanged (Agreement/
Concordance)
Positive in primary but
negative in metastatic
carcinoma
Negative in primary but
positive in metastatic
carcinoma
Total discrepant cases
(Discordance)

No (%)

No (%)

No (%)

22 (22%)

19 (19%)

42 (42%)

69 (69%)

69 (69%)

53 (53%)

22+69=91
(91%)

19+69=88
(88%)

42+53=95
(95%)

6 (6%)

9 (9%)

2 (2%)

3 (3%)

3 (3%)

3 (3%)

6+3=9
(9%)

9+3=12
(12%)

2+3=5
(5%)

Total number of patients = 100.

positive cells was almost same in most of the cases. HER2/neu expression ranged from negative (1+) to weakly
positive (2+) to strongly positive (3+). Metastases showed
almost same proportion and intensity of HER-2/neu over
expression as in primary tumours.

Discussion

Breast cancer is a typically sex hormone dependant
neoplasm and estrogen is believed to play an important role in
the pathogenesis and initial proliferation of this tumour.
Estrogen binds to the estrogen receptor (ER) resulting in an
activated complex that acts as a transcription factor through
binding to the target genes. Estrogen dependant growth can be
blocked by anti-estrogen, which competes for binding to the
estrogen receptor. The evaluation of ER expression in the
breast tissue has brought about prominent developments in the
treatment of breast cancer, especially in the area of endocrine
therapy. Further more ER expression is a prognostic indicator
and ER positive breast cancer patients show significantly
longer survival and disease-free intervals. ER status of a
patient with breast carcinoma is usually determined only on
the basis of ER content in the primary carcinomas as it is
generally assumed that ER content of the metastases is similar
to that of primary carcinomas. If metastatic tumours have an
ER status different from that of primary tumour, the
implication of ER expression may differ between primary and
metastatic lesions and hormone status has to be separately
established in metastatic deposits. Metastatic tumours have
been reported as being less frequently receptor positive than
primary tumours, although there appears to be reasonable
agreement in the receptor status between primary tumour and
involved regional lymph nodes.
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In this study, hormonal receptor status was compared
between primary and metastatic tumours to the axillary lymph
nodes. Estrogen receptor positivity was observed in 28%
primary breast carcinomas and its expression reduced to 25%
in metastatic carcinoma to the corresponding lymph nodes
with P value of 0.7488. Progesterone receptors were positive
in 28% primary tumours with reduced expression to 22% in
metastatic carcinomas with P value of 0.4144. Both of these P
values are not significant confirming that the difference of
estrogen and progesterone receptor expression between
primary and metastatic carcinoma is not statistically
significant. When case to case comparison was done, estrogen
and progesterone receptors showed 91% and 88%
concordance respectively, again confirming that primary and
metastatic tumours express hormonal receptors with
reasonable agreement. The mild difference which is noted in
this study is statistically not significant.

A number of studies compared estrogen and
progesterone receptor status between primary and metastatic
carcinomas to corresponding lymph nodes. In 2003, Iguchi
and colleagues evaluated 87 patients for estrogen receptor
expression in primary and metastatic carcinoma to the
corresponding lymph nodes. Their study showed 75.9%
concordance between primary tumour and metastases, 23%
cases were ER positive and 52.9% were negative both in
primary and metastatic tumours. ER expression differed in
24.1% cases.12 In 1995, Nedergaard L evaluated 101 patients.
ER status in primary and metastatic tumours was concordant
in 79% (80) patients and discordant in 21% (21) cases.13 In
1983 Holdaway showed 46% concordance between primary
and secondary tumours for estrogen and progesterone
receptors.20 Mori and Morimoto in 1991 showed decreased
expression and intensity of estrogen receptors in metastases to
the lymph nodes.21 In 1995 Van Agthoven studied 26 cases
with lymph node metastases. ER was positive in 19 (73%)
primary tumours and 18 (69%) lymph node metastases. PR
was detected in 63% of primary tumours and 62% of lymph
node metastases.15 Klinga K and colleagues also showed the
same results. They found 68% concordance for estrogen
receptors and 74% for progesterone receptors.22 Cianga C
showed that 30% breast carcinomas lost their expression of
hormone receptors from primary tumours to axillary
metastases.23 Hoehn and Plotka in 1979 got 81% agreement
between primary and metastatic carcinoma for estrogen
receptors.24 In our study, we obtained comparable results with
those described in previous studies.
ER status is one of the standard criteria for determining
the indication of endocrine therapy. However, the presence of
ER is no warrant for response to endocrine therapy because 40
to 50% patients with ER positive primary tumours do not
respond and almost all patients ultimately develop metastases
refractory to treatment. About 10% ER negative carcinomas
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are hormone dependent. Many mechanisms may potentially
be responsible for these controversial observations. Previous
reports show that there are functional variants of ER and ER β
which may contribute. Moreover ER status in the primary
tumour and involved corresponding lymph nodes has been
found to be discordant in about 15% and 30% cases. This
discordance of ER status may be due to loss of estrogen
receptors during the process of metastases as we see in all
these studies. Tumour heterogeneity probably also plays an
important role. Estrogen and progesterone receptor positive
primary tumours contain small percentage of cells which do
not express hormone receptors. These cells represent the
poorly differentiated population of cells which have the
potential to metastasize to distant sites and usually do not
respond to the endocrine therapy. This view is supported by a
study in which ER content of 60 primary breast carcinomas
and their lymph node metastases was investigated. Samples of
primary tumour were examined for ER and were classified as
"positive" if all samples were positive, ER "negative" if all
were negative and "heterogeneous" if some were positive and
some were negative. The study showed that 17 out of 20
heterogeneous tumours (85%) had ER negative lymph node
metastases. All uniformly negative tumours had negative
metastases.25 There is loss of Estrogen and Progesterone
receptor expression in our study as well (Table-2). This
observation may explain why some hormone receptor positive
tumours did not respond to endocrine therapy.

HER-2/neu proto-oncogene is over expressed in 25%
to 30% of human breast cancers and is usually associated with
tumour aggressiveness and poor prognosis. HER-2/neu is
analyzed as an approach to predict the response of individual
tumours to chemotherapy as well as in the use of recombinant
humanized antibodies (transtuzumab) to the HER-2/neu
protein in the active management of patients with metastatic
breast disease.11 The main targets of any therapy in metastatic
breast cancer are the metastases. However, in great majority of
cases, HER-2/neu status is determined on the primary tumour.
Studies have reported a high level of consistency, although not
complete, in HER-2/neu between primary and loco-regional
metastases using immunohisochemistry.
Her-2/neu protein over expression was noted in 44%
primary breast tumours which was almost same as in the
metastatic tumours. It was over expressed in 45% metastatic
tumours, with no statistical difference between primary and
metastatic tumours. In 1999 Tuziak and Olszewski evaluated
71 cases of breast cancer. They found HER-2/neu over
expression in 40.8% primary and 40.9% metastatic tumours.16
A study by Tanner and Jarvinen showed amplification in 28%
of primary tumours always associated with amplification in
their metastases.17 In 2000, Shimizu et al evaluated HER-2
protein levels by immunohistochemistry, in primary and
metastatic cancer samples from 21 patients. The authors found
J Pak Med Assoc

no significant differences in the HER-2/neu expression
between primary tumours and their metastases.26 In 2000,
Masood et al evaluated HER-2 over expression in 56 patients
by immunohisochemistry. The pattern and intensity of Her-2
over expression were found to be almost identical, with
heterogeneity present in only one case.27 Our study showed
95% agreement between primary and metastases which are
comparable with previous studies.

Conclusion

Estrogen and progesterone receptors and HER-2/neu
protein expression showed significant concordance between
primary and metastatic breast carcinoma to the corresponding
lymph nodes. Hormone receptor status is usually determined
only on the basis of receptor content in the primary tumours as
it is generally assumed that hormone receptor content of the
metastases is similar to that of primary carcinomas. Our study
favors previous concept because there is no statistically
significant difference of hormone receptor expression between
primary and metastatic tumours. On the other hand metastatic
deposits in the lymph nodes can also be used to assess
hormone receptor status in the third world setting, when tissue
from the primary tumour is not available for receptor analysis.
However there are a small percentage of ER and PR positive
patients in which metastatic deposits do not express hormone
receptors. Therefore the patients who developed distant
metastasis despite the endocrine therapy may undergo
radiologically assisted biopsies and get hormone assays done
in order to know the exact status of the hormone receptor
expression.
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